



OMALIZUMAB
for Chronic Idiopathic Urticaria
SPECIAL AUTHORIZATION REQUEST FORM

Please complete all required sections to allow your request to be processed.

PATIENT INFORMATION

Patients may or may not meet eligibility requirements as established
by Alberta government-sponsored drug programs.

PATIENT LAST NAME	FIRST NAME	INITIAL	COVERAGE TYPE
BIRTH DATE (YYYY-MM-DD)	ALBERTA PERSONAL HEALTH NUMBER		<input type="checkbox"/> Alberta Blue Cross <input type="checkbox"/> Alberta Human Services <input type="checkbox"/> Other _____
STREET ADDRESS	CITY	PROV.	POSTAL CODE
			ID/CLIENT/COVERAGE NUMBER

PRESCRIBER INFORMATION

PRESCRIBER LAST NAME	FIRST NAME	INITIAL	PRESCRIBER PROFESSIONAL ASSOCIATION REGISTRATION
STREET ADDRESS			<input type="checkbox"/> CPSA <input type="checkbox"/> ACO REGISTRATION NUMBER <input type="checkbox"/> CARNA <input type="checkbox"/> ADA+C <input type="checkbox"/> ACP <input type="checkbox"/> Other
CITY, PROVINCE	PHONE		FAX
POSTAL CODE	FAX NUMBER MUST BE PROVIDED WITH EACH REQUEST SUBMITTED		

Please provide the following information for ALL requests

Diagnosis	Please indicate if this patient is
<input type="checkbox"/> Moderate to severe Chronic Idiopathic Urticaria (CIU)	<input type="checkbox"/> Starting drug upon approval complete section I
<input type="checkbox"/> Other (specify) _____	<input type="checkbox"/> New to coverage but currently maintained on drug ... complete section I and II <input type="checkbox"/> Renewal request complete section II

Section I: Please provide pre-treatment information for all INITIAL requests

i) Has the patient had a therapeutic trial with H1 antihistamines?
<input type="checkbox"/> Yes → a) Specify H1 antihistamines used _____ b) Specify response to therapy <input type="checkbox"/> Failure <input type="checkbox"/> Intolerance <input type="checkbox"/> Other (specify) _____
<input type="checkbox"/> No → Provide reason _____
ii) Were oral therapies other than H1 antihistamines tried?
<input type="checkbox"/> Yes → Specify drugs utilized, including dose, duration and patient's response _____ <input type="checkbox"/> No → Provide reason _____
iii) Baseline (pre-treatment) measure of disease severity Urticaria Activity Score over seven days (UAS7) _____ Date _____
iv) Is the patient currently on therapy with omalizumab? <input type="checkbox"/> Yes → Indicate start date of therapy _____ <input type="checkbox"/> No

Section II: Complete for ADDITIONAL 24-WEEK TREATMENT COURSE requests and TREATMENT RE-INITIATION requests

i) Measure of disease severity at the end of the previous 24-week treatment course of omalizumab UAS7 score _____ Date _____
ii) If the patient's UAS7 score recorded above for i) is zero (0), was this complete symptom control maintained for at least 12 consecutive weeks? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not applicable (patient's UAS7 at the end of treatment was not zero)
iii) Has omalizumab been discontinued due to temporary symptom control? <input type="checkbox"/> Yes → Answer a) and b) below <input type="checkbox"/> No a) Provide the date of discontinuation of previous course of omalizumab _____ b) Provide the current measure of disease severity: UAS7 score _____ Date _____

Additional information relating to request

PRESCRIBER'S SIGNATURE	DATE (YYYY-MM-DD)	Please forward this request to Alberta Blue Cross, Clinical Drug Services 10009 108 Street NW, Edmonton, Alberta T5J 3C5 FAX: 780-498-8384 in Edmonton • 1-877-828-4106 toll free all other areas
ONCE YOUR REQUEST HAS SUCCESSFULLY TRANSMITTED, PLEASE DO NOT MAIL OR RE-FAX YOUR REQUEST		

The information collected by this form is collected pursuant to sections 20, 21 and 22 of the Health Information Act, and sections 33 and 34 of the Freedom of Information and Protection of Privacy Act, for the purpose of determining or verifying eligibility to participate in a program or receive a benefit, product or health service. If you have any questions regarding the collection or use of this information, please contact an Alberta Blue Cross privacy matters representative toll-free at 1-855-498-7302 or write to Privacy Matters, Alberta Blue Cross, 10009 - 108 Street, Edmonton AB T5J 3C5.

®The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. ® Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 60056 (2018/03)





**OMALIZUMAB
for Chronic Idiopathic Urticaria
SPECIAL AUTHORIZATION CRITERIA**

Patients may or may not meet eligibility requirements as established by Alberta government-sponsored drug programs.

Criteria for coverage

For the treatment of adults and adolescents (12 years of age and above) with moderate to severe chronic idiopathic urticaria (CIU), defined as having a baseline Urticaria Activity Score over seven days (UAS7) of greater than or equal to 16, who remain symptomatic (presence of hives and/or associated itching) despite optimum management with available oral therapies. Oral therapies should include a therapeutic trial with H₁ antihistamines, unless contraindicated or not tolerated.

For coverage, the drug must be initiated and monitored by a Specialist in Dermatology, Clinical Immunology or Allergy.

Coverage may be approved for a period of 24 weeks at a maximum dose of 300 mg every four weeks.

Patients will be limited to receiving a one-month supply of omalizumab per prescription at their pharmacy.

Patients are limited to receiving one biologic agent at a time regardless of the condition for which it is being prescribed.

Continued coverage of a further 24-week treatment period may be considered if the patient has experienced:

- complete symptom control (i.e. UAS7 of 0) for less than 12 consecutive weeks; OR
- partial symptom control, with a reduction in baseline UAS7 of greater than or equal to 9.5 points.

Treatment cessation should be considered for patients who experience complete symptom control for at least 12 consecutive weeks at the end of a 24-week treatment period.

In patients where treatment is discontinued due to temporary symptom control, treatment re-initiation should be considered should CIU symptoms reappear.